a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥60 ml/min 8. Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease. 9. Eligible for treatment with paclitaxel, doxorubicin, cyclophosphamide and carboplatine. 10.Patient must be accessible for treatment and follow-up. 11.Patients must be willing to undergo research biopsies to obtain breast cancer tissue for whole exome sequencing and evaluation of tumor immune microenvironment. 12.All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.